2022
DOI: 10.3390/jcm11195781
|View full text |Cite
|
Sign up to set email alerts
|

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals

Abstract: Background: Chronic hepatitis C (CHC) is associated with hepatic and extrahepatic complications, including cardiovascular disease (CVD). The effects of sustained virological response (SVR) and liver fibrosis on CVD risk are not well established. Aims: We aim to assess the dynamics of Fibrosis-4 (FIB-4) and Atherosclerotic Cardiovascular Disease 2013 (ASCVD) scores up to three years after direct acting antivirals (DAA) treatment and explore the time-dependent association between the two scores. Methods: We incl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 66 publications
0
1
0
Order By: Relevance
“…Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are markers of systemic immune response that could be potentially used as prognostic for HCV infection severity [ 57 ], for HCC outcomes [ 58 ] and also for a range of other chronic hepatic diseases [ 59 , 60 ]. Dyslipidaemia [ 61 , 62 ] and insulin resistance [ 63 ] were also previously associated with the severity of HCV complications. We acknowledge that the present study did not analyse these potentially useful biomarkers, which could perhaps be incorporated in further studies.…”
Section: Discussionmentioning
confidence: 99%
“…Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are markers of systemic immune response that could be potentially used as prognostic for HCV infection severity [ 57 ], for HCC outcomes [ 58 ] and also for a range of other chronic hepatic diseases [ 59 , 60 ]. Dyslipidaemia [ 61 , 62 ] and insulin resistance [ 63 ] were also previously associated with the severity of HCV complications. We acknowledge that the present study did not analyse these potentially useful biomarkers, which could perhaps be incorporated in further studies.…”
Section: Discussionmentioning
confidence: 99%